$AWH
Aspira Women's Health Inc.

2023 Q4 Form 10-Q Financial Statement

#000092661723000095 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.130M $2.217M
YoY Change -1.07% 7.0%
Cost Of Revenue $911.0K $910.0K
YoY Change -0.65% -0.66%
Gross Profit $1.219M $1.307M
YoY Change -1.38% 13.06%
Gross Profit Margin 57.23% 58.95%
Selling, General & Admin $4.277M $4.425M
YoY Change -26.25% -49.11%
% of Gross Profit 350.86% 338.56%
Research & Development $1.077M $998.0K
YoY Change 3.76% -53.73%
% of Gross Profit 88.35% 76.36%
Depreciation & Amortization $39.00K $40.00K
YoY Change -43.48% -40.3%
% of Gross Profit 3.2% 3.06%
Operating Expenses $5.354M $5.423M
YoY Change -21.69% -50.03%
Operating Profit -$4.135M -$4.116M
YoY Change -26.17% -57.55%
Interest Expense $2.000K $10.00K
YoY Change -92.59% -99.8%
% of Operating Profit
Other Income/Expense, Net $44.00K $599.0K
YoY Change -90.7% 411.97%
Pretax Income -$3.089M -$4.710M
YoY Change -39.44% 3.33%
Income Tax
% Of Pretax Income
Net Earnings -$3.089M -$4.706M
YoY Change -39.44% 3.25%
Net Earnings / Revenue -145.02% -212.27%
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.30 -$0.48
COMMON SHARES
Basic Shares Outstanding 10.34M 10.20M
Diluted Shares Outstanding 9.776M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.597M $5.100M
YoY Change -80.48% -75.18%
Cash & Equivalents $2.597M $5.100M
Short-Term Investments
Other Short-Term Assets $997.0K $600.0K
YoY Change -30.86% -36.44%
Inventory $227.0K $301.0K
Prepaid Expenses
Receivables $1.459M $1.590M
Other Receivables $0.00 $0.00
Total Short-Term Assets $5.280M $7.572M
YoY Change -67.63% -67.04%
LONG-TERM ASSETS
Property, Plant & Equipment $693.0K $221.0K
YoY Change 6.62% -47.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $289.0K $13.00K
YoY Change -30.19% -94.8%
Total Long-Term Assets $982.0K $1.090M
YoY Change -7.71% 12.84%
TOTAL ASSETS
Total Short-Term Assets $5.280M $7.572M
Total Long-Term Assets $982.0K $1.090M
Total Assets $6.262M $8.662M
YoY Change -63.96% -63.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.261M $1.382M
YoY Change 43.13% -26.99%
Accrued Expenses $3.022M $3.089M
YoY Change -18.92% -38.07%
Deferred Revenue
YoY Change
Short-Term Debt $670.0K $77.00K
YoY Change -12.3%
Long-Term Debt Due $166.0K $378.0K
YoY Change -58.81% 10.2%
Total Short-Term Liabilities $5.119M $5.162M
YoY Change -11.36% -29.26%
LONG-TERM LIABILITIES
Long-Term Debt $1.430M $1.217M
YoY Change -38.23% -49.84%
Other Long-Term Liabilities $2.078M $2.900M
YoY Change -18.57% -4.64%
Total Long-Term Liabilities $3.508M $1.217M
YoY Change -27.92% -49.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.119M $5.162M
Total Long-Term Liabilities $3.508M $1.217M
Total Liabilities $8.627M $9.321M
YoY Change -18.93% -26.97%
SHAREHOLDERS EQUITY
Retained Earnings -$518.3M -$515.2M
YoY Change 3.89% 4.34%
Common Stock $11.00K $11.00K
YoY Change -91.2% -91.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.365M -$659.0K
YoY Change
Total Liabilities & Shareholders Equity $6.262M $8.662M
YoY Change -63.96% -63.82%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.089M -$4.706M
YoY Change -39.44% 3.25%
Depreciation, Depletion And Amortization $39.00K $40.00K
YoY Change -43.48% -40.3%
Cash From Operating Activities -$3.454M $3.321M
YoY Change -51.19% -138.47%
INVESTING ACTIVITIES
Capital Expenditures $14.00K $0.00
YoY Change -81.08% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.00K $0.00
YoY Change -81.08% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 956.0K 4.180M
YoY Change -1117.02% -52.26%
NET CHANGE
Cash From Operating Activities -3.454M 3.321M
Cash From Investing Activities -14.00K 0.000
Cash From Financing Activities 956.0K 4.180M
Net Change In Cash -2.512M 3.321M
YoY Change -65.32% 4577.46%
FREE CASH FLOW
Cash From Operating Activities -$3.454M $3.321M
Capital Expenditures $14.00K $0.00
Free Cash Flow -$3.468M $3.321M
YoY Change -51.5% -138.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Central Index Key
EntityCentralIndexKey
0000926617
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34810
dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
519-0400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AWH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10336834
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5100000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13306000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
35000000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
9000000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1590000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1245000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
581000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1442000
CY2023Q3 us-gaap Inventory Net
InventoryNet
301000
CY2022Q4 us-gaap Inventory Net
InventoryNet
316000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
7572000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16309000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
221000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
600000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
282000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
256000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
163000
CY2023Q3 us-gaap Assets
Assets
8662000
CY2022Q4 us-gaap Assets
Assets
17373000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1382000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
881000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3089000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3402000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
378000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
77000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
764000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
236000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5162000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5527000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1217000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
429000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2513000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2280000
CY2023Q3 us-gaap Liabilities
Liabilities
9321000
CY2022Q4 us-gaap Liabilities
Liabilities
10394000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10287182
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10287182
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8306326
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8306326
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
514544000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
508584000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-515214000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-501613000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-659000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6979000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8662000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17373000
CY2023Q3 us-gaap Revenues
Revenues
2217000
CY2022Q3 us-gaap Revenues
Revenues
2072000
us-gaap Revenues
Revenues
7024000
us-gaap Revenues
Revenues
6031000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
910000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
916000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2981000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2948000
CY2023Q3 us-gaap Gross Profit
GrossProfit
1307000
CY2022Q3 us-gaap Gross Profit
GrossProfit
1156000
us-gaap Gross Profit
GrossProfit
4043000
us-gaap Gross Profit
GrossProfit
3083000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
998000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2157000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2958000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4915000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1702000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3950000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6069000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12027000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2723000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3629000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9733000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12188000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5423000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9736000
us-gaap Operating Expenses
OperatingExpenses
18760000
us-gaap Operating Expenses
OperatingExpenses
29130000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4116000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8580000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14717000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26047000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1201000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1236000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
233000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1236000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
18000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
46000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
599000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-457000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1303000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-473000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4706000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7783000
us-gaap Net Income Loss
NetIncomeLoss
-13601000
us-gaap Net Income Loss
NetIncomeLoss
-25294000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9776436
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9776436
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7807876
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7807876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8838342
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8838342
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7590872
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7590872
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6979000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6578000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
396000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
827000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2317000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38000
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
178000
CY2023Q2 awh Common Stock Value Issued For Entering Into Equity Line Of Credit
CommonStockValueIssuedForEnteringIntoEquityLineOfCredit
258000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
264000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-528000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4706000
CY2023Q3 awh Common Stock Issued Under Registered Direct Offering Net Of Issuance Costs
CommonStockIssuedUnderRegisteredDirectOfferingNetOfIssuanceCosts
4157000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
421000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-3000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-659000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9268000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
838000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8243000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
140000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
470000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14122000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7783000
CY2022Q3 awh Common Stock And Warrants Issued Value
CommonStockAndWarrantsIssuedValue
4293000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
95000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
451000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11178000
us-gaap Net Income Loss
NetIncomeLoss
-13601000
us-gaap Net Income Loss
NetIncomeLoss
-25294000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
-2000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
162000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
195000
us-gaap Share Based Compensation
ShareBasedCompensation
1302000
us-gaap Share Based Compensation
ShareBasedCompensation
1994000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
233000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1236000
awh Other Expenses Representing Transaction Costs Allocated To Issuance Of Warrants
OtherExpensesRepresentingTransactionCostsAllocatedToIssuanceOfWarrants
574000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
258000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
345000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
174000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1011000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-694000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-15000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
106000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-474000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-653000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12444000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23992000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
158000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
148000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
196000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
202000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
134000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
178000
awh Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
4716000
awh Payment Of Issuance Costs For Registered Direct Offering
PaymentOfIssuanceCostsForRegisteredDirectOffering
559000
awh Proceeds From Public Offering
ProceedsFromPublicOffering
9000000
awh Payment Of Issuance Costs For Public Offering
PaymentOfIssuanceCostsForPublicOffering
1296000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4255000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7521000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8201000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16629000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5356000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20801000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5100000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20551000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
256000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5356000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20801000
us-gaap Interest Paid Net
InterestPaidNet
41000
us-gaap Interest Paid Net
InterestPaidNet
57000
us-gaap Line Of Credit Facility Decrease Forgiveness1
LineOfCreditFacilityDecreaseForgiveness1
1000000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
258000
awh Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
318000
awh Warrants Issued Fair Value
WarrantsIssuedFairValue
3984000
us-gaap Nature Of Operations
NatureOfOperations
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Organization </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Aspira Women’s Health Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company</span><span id="BKMK_206" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">”) is incorporated in the state of Delaware, and is engaged in the business of discovering, developing and commercializing risk assessment and diagnostic tests for gynecologic diseases. The Company currently markets and distributes the following products and related services: (1) Ova1Plus, a non-invasive blood test that combines two FDA-cleared tests for women with pelvic masses who are planned for surgery: Ova1, leveraging its high sensitivity, and Overa, with its high specificity; and (2) OvaWatch, a non-invasive blood test used to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment as likely benign or indeterminant with a negative predictive value of 99%.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Collectively, these tests are referred to and marketed as OvaSuite.</span><span style="white-space:pre-wrap; font-family: 'Segoe UI', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue from these sources is included in total revenue in the results of operations for the three and nine months ended September 30, 2023 and 2022, respectively.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5100000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
256000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-515214000
CY2023Q3 awh Working Capital
WorkingCapital
2410000
us-gaap Net Income Loss
NetIncomeLoss
-13601000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3321000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12444000
CY2023Q3 awh Market Capitalisation
MarketCapitalisation
35000000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
awh Adjustments To Estimates Of Variable Consideration To Derecognize Revenue
AdjustmentsToEstimatesOfVariableConsiderationToDerecognizeRevenue
0
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
115000
CY2022Q3 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2022Q3 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023Q3 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023Q3 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20551000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
6000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1201000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
944000
CY2022Q3 us-gaap Inventory Net
InventoryNet
280000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
22976000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
417000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q3 us-gaap Assets
Assets
23942000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1893000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4988000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
343000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
73000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7297000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2426000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
293000
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2748000
CY2022Q3 us-gaap Liabilities
Liabilities
12764000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8296376
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8296376
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7475916
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7475916
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
508192000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-497022000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11178000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23942000
CY2022Q3 us-gaap Revenues
Revenues
2072000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
916000
CY2022Q3 us-gaap Gross Profit
GrossProfit
1156000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2157000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3950000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3629000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9736000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8580000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1236000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
18000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-457000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7783000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7807876
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7807876
us-gaap Revenues
Revenues
6031000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2948000
us-gaap Gross Profit
GrossProfit
3083000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4915000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12027000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12188000
us-gaap Operating Expenses
OperatingExpenses
29130000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26047000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1236000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-473000
us-gaap Net Income Loss
NetIncomeLoss
-25294000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7590872
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7590872
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9268000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
838000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8243000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
140000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
470000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14122000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7783000
CY2022Q3 awh Common Stock And Warrants Issued Value
CommonStockAndWarrantsIssuedValue
4293000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
95000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
451000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11178000
us-gaap Net Income Loss
NetIncomeLoss
-25294000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
195000
us-gaap Share Based Compensation
ShareBasedCompensation
1994000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1236000
awh Other Expenses Representing Transaction Costs Allocated To Issuance Of Warrants
OtherExpensesRepresentingTransactionCostsAllocatedToIssuanceOfWarrants
574000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
174000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-694000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
106000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-653000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23992000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
158000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
196000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
awh Proceeds From Public Offering
ProceedsFromPublicOffering
9000000
awh Payment Of Issuance Costs For Public Offering
PaymentOfIssuanceCostsForPublicOffering
1296000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7521000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16629000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20801000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20551000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20801000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
78000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
767000
CY2023Q3 awh Prepaid Software Licenses
PrepaidSoftwareLicenses
155000
CY2022Q4 awh Prepaid Software Licenses
PrepaidSoftwareLicenses
269000
CY2023Q3 awh Prepaid Subscriptions
PrepaidSubscriptions
4000
CY2022Q4 awh Prepaid Subscriptions
PrepaidSubscriptions
211000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
344000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
195000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
581000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1442000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
1595000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
2718000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
378000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1217000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2023Q3 us-gaap Contractual Obligation
ContractualObligation
1604000
CY2023Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
26000
CY2023Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
475000
CY2023Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
485000
CY2023Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
477000
CY2023Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
141000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
85000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
245000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
225000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
170000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
18000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
743000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
78000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
665000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
236000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
429000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
123000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
89000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0808
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0931
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1640000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1803000
CY2023Q3 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
121000
CY2022Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
404000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
669000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
659000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
639000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3089000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3402000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 awh Stock Issuance Expenses
StockIssuanceExpenses
0
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.20
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4706000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7783000
us-gaap Net Income Loss
NetIncomeLoss
-13601000
us-gaap Net Income Loss
NetIncomeLoss
-25294000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9776436
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9776436
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7807876
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7807876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8838342
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8838342
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7590872
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7590872
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33

Files In Submission

Name View Source Status
awh-20230930_cal.xml Edgar Link unprocessable
awh-20230930_def.xml Edgar Link unprocessable
awh-20230930_lab.xml Edgar Link unprocessable
awh-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000926617-23-000095-index-headers.html Edgar Link pending
0000926617-23-000095-index.html Edgar Link pending
0000926617-23-000095.txt Edgar Link pending
0000926617-23-000095-xbrl.zip Edgar Link pending
awh-20230930.xsd Edgar Link pending
awh-20230930x10q.htm Edgar Link pending
awh-20230930xex31_1.htm Edgar Link pending
awh-20230930xex31_2.htm Edgar Link pending
awh-20230930xex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
awh-20230930x10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending